Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - human papillomavirus type 6 l1 capsid protein antigen (unii: 61746o90dy) (human papillomavirus type 6 l1 capsid protein antigen - unii:61746o90dy), human papillomavirus type 11 l1 capsid protein antigen (unii: z845vhq61p) (human papillomavirus type 11 l1 capsid protein antigen - unii:z845vhq61p), human papillomavirus type 16 l1 capsid protein antigen (unii: 6lte2dnx63) (human papillomavirus type 16 l1 capsid protein antigen - unii:6lte2dnx63), human papillomavirus type 18 l1 capsid protein antigen (unii: - human papillomavirus type 6 l1 capsid protein antigen 30 ug in 0.5 ml - gardasil® 9 is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases: - cervical, vulvar, vaginal, and anal cancer caused by human papillomavirus (hpv) types 16, 18, 31, 33, 45, 52, and 58 - genital warts (condyloma acuminata) caused by hpv types 6 and 11 and the following precancerous or dysplastic lesions caused by hpv types 6, 11, 16, 18, 31, 33, 45, 52, and 58: - cervical intraepithelial neoplasia (cin) grade 2/3 and cervical adenocarcinoma in situ (ais) - cervical intraepithelial neoplasia (cin) grade 1 - vulvar intraepithelial neoplasia (vin) grade 2 and grade 3 - vaginal intraepithelial neoplasia (vain) grade 2 and grade 3 - anal intraepithelial neoplasia (ain) grades 1, 2, and 3 gardasil 9 is indicated in boys and men 9 through 26 years of age for the prevention of the following diseases: - anal cancer caused by hpv types 16, 18, 31, 33, 45, 52, and 58 - genital warts (condyloma acuminata) caused by hpv types 6 and 11 and the following

Euroopan unioni - englanti - EMA (European Medicines Agency)

xbiotech germany gmbh - human igg1 monoclonal antibody specific for human interleukin-1 alpha - colorectal neoplasms - antineoplastic agents - treatment of metastatic colorectal cancer

Yhdysvallat - englanti - NLM (National Library of Medicine)

deseret biologicals, inc. - human papillomavirus (unii: 23cvl7wf4j) (human papillomavirus - unii:23cvl7wf4j) - for the temporary relief of symptoms related to human papilloma virus including itching in the pelvic area.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to human papilloma virus including itching in the pelvic area.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - human albumin -

Israel - englanti - Ministry of Health

csl behring ltd., israel - human fibrinogen - powder for solution for inj/inf - human fibrinogen 900 - 1300 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

Israel - englanti - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - solution for infusion - human hepatitis b immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - prophylaxis against hepatitis b in adults and children over 2 years of age who have not been vaccinated against hepatitis b (including persons whose vaccination is incomplete or missing) who are at risk of infection with hepatitis b by accidental contact with hepatitis b virus containing material following: - percutaneous exposure (e.g. accidental needle stick). - direct mucous membrane contact. when the administration of an intramuscular hepatitis b immunoglobulin is not possible. the immunoglobulin should be administered in association with hepatitis b vaccine. prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of the hepatitis b virus. immunoprophylaxis of hepatitis b in the newborn of a hepatitis b virus carrier mother.

Israel - englanti - Ministry of Health

kamada ltd, israel - human normal immunoglobulin - solution for infusion - human normal immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents (0-18 years) in:- primary immunodeficiency syndromes (pid) with impaired antibody production- secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of <4 g/l* psaf= failure to mount at least a 2-fold rise in igg antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccinesimmunomodulation in adults, and children and adolescents (0-18 years) in:- primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count- guillain barré syndrome- kawasaki disease (in conjunction with acetylsalicylic acid)- chronic inflammatory demyelinating polyradiculoneuropathy (cidp)- multifocal motor neuropathy (mmn)

Singapore - englanti - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - albumin (human serum) (venous) - injection - 5.00% - albumin (human serum) (venous) 5%

Singapore - englanti - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - albumin (human serum) (venous) - infusion, solution - 0.2 g/ml - albumin (human serum) (venous) 0.2 g/ml

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - plasma protein containing at least 95% human albumin - solution for infusion - 50 gram(s)/litre - blood substitutes and plasma protein fractions; albumin - plasma substitutes and plasma protein fractions - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate.